Jeremy Chan
About Jeremy Chan
Jeremy Chan is a Research Associate specializing in Non-Viral Gene Delivery Technologies at Bristol Myers Squibb in Seattle, Washington. He holds a B.S. in Biochemistry and Microbiology from the University of Washington and has prior experience at Seattle Children's Autism Center and the Immunotherapy Integration Hub at Seattle Children's.
Current Position at Bristol Myers Squibb
Jeremy Chan is currently working as a Research Associate specializing in Non-Viral Gene Delivery Technologies at Bristol Myers Squibb. Based in Seattle, Washington, he has been with the company since September 2020. In this role, he focuses on advancing gene delivery methods that do not involve viral vectors, contributing to innovative therapeutic solutions.
Previous Experience at Seattle Children's Autism Center
In 2019, Jeremy Chan served as a Resource Intern at Seattle Children's Autism Center for a duration of five months. This role provided him with valuable experience in autism research and patient support, further augmenting his scientific and clinical expertise.
Role at Seattle Children's Immunotherapy Integration Hub
From 2018 to 2020, Jeremy Chan worked as an Undergraduate Research Assistant at Seattle Children's Immunotherapy Integration Hub, specifically in the Jensen Lab. During his two-year tenure, he gained hands-on experience in immunotherapy research, contributing to the lab's ongoing projects focusing on innovative cancer therapies.
Educational Background in Biochemistry and Microbiology
Jeremy Chan holds a Bachelor of Science degree in Biochemistry and Microbiology from the University of Washington. His academic background provides a strong foundation for his research work, particularly in the field of gene delivery and immunotherapy. The rigorous training at the University of Washington has equipped him with the essential skills and knowledge needed for his current role.
Specialization in Non-Viral Gene Delivery Technologies
Jeremy Chan specializes in Non-Viral Gene Delivery Technologies, focusing on developing methods to deliver genetic material into cells without using viral vectors. His expertise in this niche area is crucial for advancing gene therapy techniques, which aim to treat genetic disorders and other diseases more safely and effectively.